Hematopoietic Stem Cell TransplantationTransplantation, HomologousStem Cell TransplantationGraft vs Host DiseaseTransplantation ConditioningStem CellsTransplantation, AutologousPeripheral Blood Stem Cell TransplantationHematologic NeoplasmsTransplantation ChimeraBone Marrow TransplantationGraft vs Leukemia EffectMyeloablative AgonistsHematopoietic Stem CellsTreatment OutcomeTissue DonorsBusulfanRemission InductionVidarabineRecurrenceGraft vs Tumor EffectGraft SurvivalHistocompatibility TestingEmbryonic Stem CellsLymphocyte TransfusionLeukemia, Myeloid, AcuteImmunosuppressive AgentsMultiple MyelomaLeukemiaAdult Stem CellsCord Blood Stem Cell TransplantationRetrospective StudiesMesenchymal Stem Cell TransplantationCombined Modality TherapyLeukemia, Myelogenous, Chronic, BCR-ABL PositiveSiblingsCytomegalovirus InfectionsMinor Histocompatibility AntigensSalvage TherapyWhole-Body IrradiationDisease-Free SurvivalLymphocyte DepletionLiver TransplantationMyelodysplastic SyndromesSurvival AnalysisAntilymphocyte SerumVirus ActivationSurvival RateNeoplasm, ResidualHistocompatibilityPrecursor Cell Lymphoblastic Leukemia-LymphomaHematopoietic Stem Cell MobilizationPluripotent Stem CellsMelphalanChimerismTime FactorsHepatic Veno-Occlusive DiseaseStem Cell NicheCyclophosphamideCell DifferentiationAntineoplastic Combined Chemotherapy ProtocolsNeural Stem CellsCytomegalovirusT-LymphocytesCell TransplantationAntigens, CD34Induced Pluripotent Stem CellsAcute DiseasePrimary MyelofibrosisAnemia, AplasticMesenchymal Stromal CellsHLA AntigensFollow-Up StudiesHematologic DiseasesKidney TransplantationLeukemia, Myeloid, Accelerated PhasePrognosisMultipotent Stem CellsTransplantation ImmunologyAntibodies, NeoplasmCytarabineBenzamidesRoseolovirus InfectionsImmunosuppressionAntineoplastic AgentsLeukemia, MyeloidImmunocompromised HostFusion Proteins, bcr-ablLymphoproliferative DisordersBone Marrow CellsHodgkin DiseaseGranulocyte Colony-Stimulating FactorFlow CytometryPyrimidinesReceptors, Purinergic P2X5Cells, CulturedStem Cell FactorNuclear FamilyGraft RejectionGanciclovir